· Research comparison

Retatrutide vs Tirzepatide

A side-by-side technical reference for researchers comparing two incretin-targeting peptides — their receptor profiles, mechanisms of action, and study applications.

Retatrutide

A triple agonist engineered to activate the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCGR) receptors. The addition of the glucagon arm introduces an energy-expenditure dimension that distinguishes it from dual agonists in metabolic research.

· Triple receptor engagement
· Long-acting acylated peptide
· Studied for metabolic and body-composition endpoints

Tirzepatide

A dual GIP/GLP-1 receptor agonist built on a GIP-derived peptide backbone with a C20 fatty diacid for albumin binding. It has become a reference compound for studying the combined incretin effect on glycemic control and appetite regulation.

· Dual GIP/GLP-1 engagement
· Once-weekly dosing in protocols
· Reference for incretin biology

Mechanism of action

Receptor profile drives the research question.

Retatrutide adds glucagon-receptor activity to the GIP/GLP-1 dual mechanism. In research models this triple profile is investigated for effects on energy expenditure, lipid metabolism, and hepatic glucose output alongside appetite and glycemic endpoints.

The glucagon component means the compound is studied with careful attention to dose titration and receptor balance, particularly in protocols examining body composition and metabolic rate.

Tirzepatide combines GIP and GLP-1 receptor activation. The dual incretin approach is widely used as a reference for studying post-prandial insulin secretion, gastric emptying, and central appetite regulation.

Its mechanism is well characterised in preclinical and clinical literature, making it a common benchmark when evaluating newer multi-receptor compounds.

Side-by-side

At a glance.

ParameterRetatrutideTirzepatide

Drug classTriple incretin agonist peptideDual incretin agonist peptide

Primary targetsGIPR · GLP-1R · GCGRGIPR · GLP-1R

Amino-acid backboneEngineered 39-mer peptide with C20 fatty diacid39-mer peptide based on native GIP sequence

Half-life in vivo~5–6 days (albumin-bound acylation)~5 days (C20 fatty diacid)

Administration routeSubcutaneousSubcutaneous

Typical study frequencyOnce weeklyOnce weekly

Key research focusMetabolic function, energy expenditure, glucagon axisGlycemic control, appetite regulation, body composition

Study applications

When to reference each compound.

Metabolic profiling

Use Retatrutide when the protocol needs to isolate the contribution of glucagon-receptor signalling to energy balance.

Dose-response work

Tirzepatide offers a large published dose-response dataset for calibration and benchmark comparisons.

Body-composition assays

Both compounds are referenced in studies examining lean-mass preservation, adipose changes, and weight trajectories.

Order Retatrutide reference material.

PeptexLab supplies Retatrutide as a Certified Reference Material in sterile vials and pre-filled pens. Submit an inquiry for pricing, stock and COA.

View Retatrutide vials View Retatrutide pen